News articles about GenMark Diagnostics (NASDAQ:GNMK) have trended somewhat negative recently, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of -0.12 on Alpha One’s scale. Alpha One also assigned media coverage about the medical equipment provider an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.

A number of research analysts have recently weighed in on GNMK shares. Canaccord Genuity set a $14.00 price target on GenMark Diagnostics and gave the company a “buy” rating in a research note on Sunday, December 25th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of GenMark Diagnostics in a research report on Wednesday, March 1st. Zacks Investment Research upgraded shares of GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Tuesday, April 11th. Finally, BTIG Research restated a “buy” rating and issued a $17.00 price objective on shares of GenMark Diagnostics in a research report on Friday, March 10th. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $15.00.

Shares of GenMark Diagnostics (NASDAQ:GNMK) traded down 1.34% during trading on Tuesday, hitting $12.54. The stock had a trading volume of 41,375 shares. GenMark Diagnostics has a 1-year low of $5.13 and a 1-year high of $13.62. The firm has a 50-day moving average of $12.58 and a 200 day moving average of $12.02. The company’s market capitalization is $590.02 million.

GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Tuesday, February 28th. The medical equipment provider reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). The business had revenue of $14.90 million for the quarter, compared to analyst estimates of $15.03 million. GenMark Diagnostics had a negative net margin of 98.17% and a negative return on equity of 114.35%. GenMark Diagnostics’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. Equities research analysts predict that GenMark Diagnostics will post ($0.96) earnings per share for the current fiscal year.

In other news, CFO Scott Mendel sold 9,098 shares of the company’s stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $12.47, for a total transaction of $113,452.06. Following the transaction, the chief financial officer now owns 142,058 shares in the company, valued at $1,771,463.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael Gleeson sold 9,569 shares of the company’s stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $12.47, for a total transaction of $119,325.43. Following the transaction, the senior vice president now owns 252,558 shares in the company, valued at approximately $3,149,398.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 95,235 shares of company stock worth $1,072,753. 7.09% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at http://www.dailypolitical.com/2017/04/18/genmark-diagnostics-gnmk-earns-daily-news-impact-rating-of-0-12.html.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

5 Day Chart for NASDAQ:GNMK

Receive News & Ratings for GenMark Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.